


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. GJE-7284
Serial No. 10/525,532

April 8, 2005

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : Not yet assigned
Applicant(s) : David Cavalla and Robert William Gristwood
Serial No. : 10/525,532
Filed : February 23, 2005
Conf. No. : Not yet assigned
For : New Therapeutic Uses of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. A copy of the International Search Report and copies of the references cited therein have been made available in the national stage file.


However, for the examiner's convenience, the applicants are attaching a copy of the International Search Report as well as copies of the documents cited in the International Search Report. Also attached is Form PTO/SB/08 listing the references.

Docket No. GJE-7284
Serial No. 10/525,532

In accordance with 37 CFR §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRS/la

Attachments: Form PTO/SB/08
International Search Report
Copies of references cited

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Application Number		10/525,532			
Filing Date		February 23, 2005			
First Named Inventor		David Cavalla			
Group Art Unit		Not yet assigned			
Examiner Name		Not yet assigned			
Attorney Docket Number		GJE-7284			
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1				
	U2				
	U3				

FOREIGN PATENT DOCUMENTS					
Exami ner Initials *	Cite No. ¹	Foreign Patent Document Kind Code ⁵ Number ⁴ (if Office ³ known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1	EP 0 150 469 A1	Mitsubishi Chemical Industries Limited	08-07-1985	
	F2	WO 96/12485 A1	Eli Lilly and Company	05-02-1996	
	F3	WO 00/15223 A1	Eli Lilly and Company	03-23-2000	
	F4	WO 02/060427 A2	Sepracor Inc.	08-08-2002	
	F5	WO 02/064543 A2	Wyeth	08-22-2002	
	F6				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	EGUCHI, J. <i>et al.</i> (1995) "Effects of MCI-225 on Memory and Glucose Utilization in Basal Forebrain-Lesioned Rats," <i>Pharmacology Biochemistry and Behavior</i> 51(4):935-939.	
	R2	EGUCHI, J. <i>et al.</i> (2001) "The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor With 5-HT ₃ Receptor Antagonism," <i>Pharmacology Biochemistry and Behavior</i> 68:677-683.	
	R3	RAO, S. G. <i>et al.</i> (2002) "The Neuropharmacology of Centrally-acting Analgesic Medicaitons in Fibromyalgia," <i>Rheumatic Disease Clinics of North America</i> 28:235-259.	
	R4	HEAL, D. J. <i>et al.</i> (1998) "Sibutramine: A Novel Anti-obesity Drug. A Review of the Pharmacological Evidence to Differentiate it From D-amphetamine and D-fenfluramine," <i>International Journal of Obesity</i> 22(supplement):S18-S28.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.